Traduction de «year-olds is found » (Néerlandais → Français) :

As a rule, the psychological state of the 35-44 year-olds is found to be less favourable, especially as far as the more severe [4+] affections are concerned, which hit 16% of those belonging to this age group.
On remarque des dispositions psychologiques généralement moins favorables pour le groupe d’âge de 35-44 ans, surtout au regard des affections plus sévères [4+], qui atteignent 16 % des personnes de cet âge.

This reflects a considerable increase in the prevalence of problems affecting men, which rises from 7% amongst the 65 to 74 year-olds to 13% amongst the over 75 year-olds.
Ceci reflète une augmentation considérable du taux de difficultés dans le chef des hommes, qui passe de 7 % chez les 65 à 74 ans à 13 % chez les plus de 75 ans.

“Splitting up genders shows that there are considerable (and significant) differences between men and women with regard to psychological difficulties (cut-off [2+]) amongst young people aged 15-24 (+ 15% amongst women), amongst the 45-54 year-olds (+10% amongst women) and amongst the 65-74 year-olds (+11% amongst women).
« La stratification par sexe révèle que les différences hommes-femmes face aux difficultés psychologiques (seuil [2+]) sont particulièrement importantes (et significatives) chez les jeunes de 15-24 ans (+15 % chez les femmes) et dans les groupes d’âge de 45-54 ans (+10 % chez les femmes) et 65-74 ans (+11 % chez les femmes).

Vandermeulen C, Roelants M, Theeten H, Depoorter AM, Van Damme P, Hoppenbrouwers K. Vaccination coverage in 14-year-old adolescents: documentation, timeliness, and sociodemographic determinants.
Vandermeulen C, Roelants M, Theeten H, Depoorter AM, Van Damme P, Hoppenbrouwers K. Vaccination coverage in 14-year-old adolescents : documentation, timeliness, and sociodemographic determinants.

Statistics show that in countries with a high standard of living, suicide usually ranges amongst the top three most common causes of death amongst fifteen to thirty-four year-olds, and that at least twice as many males as females commit suicide.
Dans les pays dont le niveau de vie est élevé, le suicide se place en général entre le premier et le troisième rang dans le tableau statistique des causes de décès pour les quinze à trente-quatre ans.

The age distribution is somewhat different between men and women. With the latter the progression through the different age groups is almost linear, going from 6% to 16%, with, however, a reduction amongst the 55-64 year-olds (8%).
Chez les hommes, la prévalence de ces troubles est de 4 % chez les personnes de 14 à 34 ans, et se stabilise ensuite autour de 6 % à 7 % jusqu’à 75 ans.

Alice T. Shaw, David G. Forcione, Subba R. Digumarthy, A. John Iafrate: Case 21-2011: A 31-Year-Old Man with ALK-Positive Adenocarcinoma of the Lung, New England Journal of Medicine, 2011; 365-2; 2-11 Een casestudy over de behandeling van een patiënt met longkanker met behulp van een gepersonaliseerde werkzame stof.
Alice T. Shaw, David G. Forcione, Subba R. Digumarthy, A. John Iafrate: Case 21-2011: A 31-Year-Old Man with ALK-Positive Adenocarcinoma of the Lung, New England Journal of Medicine, 2011; 365-2; 2-11 Étude de cas sur le traitement par un agent personnalisé d'un patient atteint d'un cancer du poumon

For men the prevalence of these disorders is 4% amongst 14-34 year-olds and then stabilises at around 6 to 7% until the age of 75. Above this age, 8% of men experience depressive disorders.
Au-delà de cet âge, 8 % des hommes connaissent des troubles dépressifs.

A further list and description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and in its reports on Form 10-Q and Form 8-K. # # # # #
A further list and description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and in its reports on Form 10-Q and Form 8-K.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.